Bortezomib/dexamethasone-based IT regimens are commonly combined with either cytotoxic agents, such as doxorubicin 6, 7 or cyclophosphamide, 5, 13, 14, 15, 16 or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results